Markets
Peptide supply requirements in 25 EU markets.
Click a country for the regulator, the published position, and every source dated and linked.
| Market | Sources | Summary |
|---|---|---|
| Austria AT | 3 sources | BASG has published a dedicated position holding that a research-use label does not change a peptide's cl... |
| Belgium BE | 3 sources | Belgium applies EU medicines law through the FAGG, which has published a GLP-1 warning. No dedicated pos... |
| Bulgaria BG | 5 sources | The BDA regulates under the national medicines law and participates in the EU counterfeit-GLP-1 warning ... |
| Croatia HR | 1 sources | HALMED has published a general rule on online medicine sales. No notice naming research-labelled peptide... |
| Czechia CZ | 2 sources | SUKL holds that most synthetic peptides meet the functional definition of a medicinal product, so classi... |
| Denmark DK | 5 sources | Laegemiddelstyrelsen maintains standing warnings, including on Melanotan. Research-chemical framing is a... |
| Estonia EE | 2 sources | Ravimiamet published a dated statement in June 2026 addressing internet-sold peptides marketed for resea... |
| Finland FI | 2 sources | Fimea has warned against injectable peptides sold through social media. Semaglutide is a prescription me... |
| France FR | 3 sources | ANSM names compounds individually in its public alerts and has issued sanitary-police decisions against ... |
| Germany DE | 2 sources | Germany applies the Arzneimittelgesetz alongside anti-doping legislation, and sets criminal thresholds f... |
| Greece GR | 4 sources | EOF issued a public warning in July 2026, and related reporting names specific compounds. Regulatory att... |
| Hungary HU | 5 sources | OGYEI regulates medicines under Act XCV of 2005. A case-by-case research permit exists for controlled su... |
| Ireland IE | 2 sources | The HPRA detained 763,027 dosage units of falsified or unauthorised medicines in 2025. Ireland is Englis... |
| Italy IT | 1 sources | AIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 supply through unauthorised ... |
| Latvia LV | 4 sources | The ZVA regulates under the Farmacijas likums and has published dated GLP-1 safety communications. No pe... |
| Lithuania LT | 4 sources | The VVKT regulates under the Farmacijos istatymas and requires a wholesale distribution licence. No posi... |
| Netherlands NL | 3 sources | The IGJ and the NVWA assess offerings jointly and have stated their position on research-use framing dir... |
| Poland PL | 2 sources | GIF and GIS have issued a joint public warning on synthetic peptides offered as chemical reagents. The P... |
| Portugal PT | 5 sources | INFARMED governs medicines under the Estatuto do Medicamento and has flagged a rise in illegal online su... |
| Romania RO | 3 sources | ANMDMR operates under the EU medicines framework and has publicly identified a fraudulent tirzepatide pr... |
| Slovakia SK | 3 sources | SUKL named BPC-157, ipamorelin and melanotan directly in a July 2025 press release tied to an INTERPOL o... |
| Slovenia SI | 2 sources | JAZMP published a dated warning on injectable peptides in April 2026 and names semaglutide and somatropi... |
| Spain ES | 2 sources | AEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to verify pharmacies through... |
| Sweden SE | 5 sources | Lakemedelsverket has a published position on Melanotan II, and a government-commissioned report quantifi... |
| Switzerland CH | 5 sources | Swissmedic regulates therapeutic products under the Heilmittelgesetz and runs a named, active cross-agen... |
| Tell us the compounds and the market you sell into. | Ask about a market |
How to read these
Every position is sourced and dated
Each market page names its regulator, carries a review date, and lists every source with a link to the issuing body, so any statement on it can be checked at origin.
Twenty-five markets, seventy-eight dated sources. This is the reference we use ourselves when a buyer asks whether a compound can be supplied into their market. It is published so the answer is available before you ask for it.
Reviewed 2026-08-20, next review 2026-11-18. Not legal advice; full terms of supply are set out in our terms.